Interim Results From WHO’s Solidarity Trial Show Remdesivir, Interferon, Other Treatments Show Little Or No Impact On Survival Among Hospitalized COVID-19 Patients

Science: Remdesivir and interferon fall flat in WHO’s megastudy of COVID-19 treatments
“One of the world’s biggest trials of COVID-19 therapies released its long-awaited interim results yesterday — and they’re a letdown. None of the four treatments in the Solidarity trial, which enrolled more than 11,000 patients in 400 hospitals around the globe, increased survival — not even the much-touted antiviral drug remdesivir. Scientists at the World Health Organization (WHO) released the data as a preprint on medRxiv last night ahead of its planned publication in the New England Journal of Medicine…” (Kupferschmidt, 10/16).

Additional coverage of the study’s interim results is available from Financial Times, The Hill, New York Times, Reuters, and The Telegraph.

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.